Ad5f35-LMPd1-2-transduced autologous dendritic cells (NCI)

N/A

Report date: 2022/02/21 15:02:33

Base Information

Drug NameAd5f35-LMPd1-2-transduced autologous dendritic cells (NCI)

Drug Alias NameLMP1/LMP2 cytotoxic T-lymphocytes vaccineAd5f35-dLMP1-LMP2-DCsAddLMP1-I-LMP2

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsVesicle associated membrane protein 1Vesicle associated membrane protein 2

Therapy Area/IndicationsNasopharyngeal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute Baylor College Of Medicine

Active IndicationsN/A

Inactive IndicationsNasopharyngeal Neoplasms

Other Information

ATC CodeN/A